This briefing discusses AI-enabled biological design and highlights related trends, opportunities and regulatory choices for the EU. AI-enabled biological design means using artificial intelligence to predict, design or modify proteins, peptides and the DNA or RNA that produce them. It has rapidly evolved over the past few years and is now in routine use across European biopharmaceutical research, industrial biotechnology and vaccine development.
← Back
AI-enabled biological design: trends, opportunities and regulatory choices for the European Union
Original title: Briefing - AI-enabled biological design - Trends, opportunities and regulatory choices for the European Union - PE 795.715 - Committee on the Environment, Public Health and Food Safety - Committee on Industry, Research and Energy - Committee on Public Health